Day: January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan.

1 child or youth died every 4.4 seconds in 2021: UN

UNITED NATIONS— An estimated 5 million children died before their fifth birthday and another 2.1 million children and youth aged between 5 and 24 years lost their lives in 2021, according to the latest estimates released by the UN Inter-agency Group fo…